Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948448 | 0.91 | HTR2A (0.57) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4237169 | 0.90 | HTR2A (0.56) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4233102 | 0.90 | HTR2A (0.56) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13948477 | 0.88 | HTR6 (0.52) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13948463 | 0.87 | HTR2A (0.49) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4233342 | 0.87 | HTR6 (0.51) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4228992 | 0.87 | HTR2A (0.53) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL4374094 | 0.87 | HTR2A (0.53) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4236535 | 0.86 | HTR2A (0.48) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4233347 | 0.86 | HTR6 (0.50) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012056-A1 | Quinoline Compounds Capable of Binding the Cb2 and/or the 5-Ht6 Receptor | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | US | claimed |
| US-20090012056-A1 | Quinoline Compounds Capable of Binding the Cb2 and/or the 5-Ht6 Receptor | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012056-A1 | Quinoline Compounds Capable of Binding the Cb2 and/or the 5-Ht6 Receptor | CNR2, CNR1, HTR6 | HTR6 3/4885HTR2A 10/4885HTR1A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.